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ABSTRACT
Nitric oxide (NO) is an important biological molecule with a variety of functions. Among 
other, it is a signalling molecule capable of inducing smooth muscle relaxation and 
vasodilatation, it regulates proliferation, can induce apoptosis and act as an effector molecule 
in host defence reactions and in immune regulatory processes. High levels of NO are also seen 
in inammatory diseases and NO is thought to play a role in tumour biology. e present 
thesis mainly focuses on the role of NO in the pathogenesis of bladder pain syndrome/
interstitial cystitis (BPS/IC), the role for NO in bladder tumour biology and its potentially 
cytotoxic effects following Bacillus Calmette Guérin (BCG) treatment.
 In bladder biopsies from patients with classic BPS/IC we found an increased inducible 
nitric oxide synthase (iNOS) expression at both transcriptional and protein levels compared 
to controls. ese ndings were correlated with high levels of endogenously formed NO in 
the same patients. iNOS expression was localized to the urothelium and macrophages both in 
the urothelial layer and in the submucosa. 
 Local NO formation in patients with bladder tumours of different stage and grade was 
increased in patients with a carcinoma in situ (CIS) lesion alone or concomitant with a 
papillary tumour as compared to healthy controls and patients with papillary bladder tumours 
without concomitant CIS. e same relationship was observed for iNOS with higher levels of 
mRNA and protein expression in patients with CIS. Aer BCG treatment for bladder cancer, 
iNOS was up regulated in the urothelium but was also seen in immune competent cells in the 
submucosa. Luminal NO was signicantly elevated, as was iNOS mRNA expression, in BCG 
treated patients compared to controls. Furthermore, iNOS protein expression was found in 
the BCG treated patients when biopsies were examined using Western blot technique. In 
patients with high-risk non-muscle invasive bladder cancer (NMIBC) polymorphisms in 
the iNOS and endothelial nitric oxide synthase (eNOS) genes inuenced treatment response 
following BCG instillations. 
 In conclusion, our results demonstrate an elevation of NO levels in the bladder in patients 
with classic BPS/IC that in all probability originate from an increased expression of iNOS in 
urothelial and immune competent cells in the bladder wall. In addition, NO levels are higher 
in patients with CIS lesions than in patients with papillary bladder tumours and this increase 
is also likely due to an elevated expression of iNOS. Furthermore, NO levels are higher in 
the bladder aer BCG treatment and are likely to reect an increased expression of iNOS in 
bladder urothelial cells and immune competent cells in the submucosa. ese ndings are in 
line with previous results implicating that BCG may act through NO/NOS pathways, which 
is further supported by our observations that polymorphisms in the iNOS and eNOS genes 
may inuence treatment outcome for BCG.
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INTRODUCTION
1.1 The history of nitric oxide
25 years ago nitric oxide (NO) was considered merely a pollutant gas, but through 
several independent discoveries the importance of NO as a biological messenger 
was discovered. In 1985, it was demonstrated that the ability to produce nitrite and 
nitrate was essential in macrophage induced bactericidal and tumouricidal activity 
(1, 2). Concomitantly, researchers attempted to characterize the chemical structure 
of endothelium derived relaxing factor (EDRF), discovered by Furchgott in 1980 
(3). In 1987 NO was shown to be equivalent to EDRF (4, 5) and at the same time 
researchers demonstrated that NO was formed in macrophages (6). e discovery 
that NO could act as a signalling molecule was awarded the Nobel Prize in 1998 
and NO had gone from being regarded a simple inorganic gas to become widely 
accepted as an important biological mediator with a multitude of functions. NO 
is involved in several biological processes, among others smooth muscle relaxation, 
regulation of vascular tone, host defence reactions and neurotransmission (7). NO 
is also a marker for objectively detecting inflammation in several organ systems, 
including the airways in asthmatic disease (8), the intestine in colitis (9) and the 
urinary bladder in cystitis of various origins (10, 11).
1.2 Nitric oxide synthases
NO is generated by a family of nitric oxide synthases (NOS). ree main isoforms, 
derived from separate genes, have been described and named after the cells in 
which they were first found (12). Two of the isoforms are constitutively expressed 
in normal cells; endothelial NOS (eNOS or NOS3) and neuronal NOS (nNOS 
or NOS1). eir activation is calcium and calmodulin dependent and occurs 
rapidly and transiently by stimuli that increase intracellular calcium levels. ese 
intracellular Ca2+ fluxes can be caused e.g by activation of muscarine receptors 
situated on endothelial cells or by the arrival of action potentials at nerve endings 
and results in small amounts of produced NO (7, 12, 13). e third isoform is 
inducible (iNOS or NOS2) and, since calmodulin is tightly bound to this enzyme 
at all times, it is not dependent of free calcium levels and has therefore been 
referred to as calcium independent. iNOS was originally identified in activated 
macrophages and produces high levels of NO in a number of cell types as a 
response to inflammatory signals such as lipopolysaccharides and cytokines (7, 12, 
13). Since iNOS, in contrast to eNOS and nNOS, is regulated at transcriptional 

and posttranscriptional levels several hours can pass between iNOS activation 
and NO production. Once induced, iNOS produces large amounts of NO over 
a prolonged period of time (7, 13) and may be lethal to, or limit the growth of, 
invading organisms and tumour cells but may also have detrimental effects on 
normal cells (14). 
 e catalyzation of NO from the conversion of L-arginine to L-citrullin requires 
the presence of molecular oxygen and reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) as well as calmodulin and several co-enzymes and co-
factors (15-17). After its production NO can diffuse across the cell membrane 
of adjacent target cells and bind to intracellular soluble guanylate cyclase (sGC), 
thus leading to the formation of cyclic guanosine-3’, 5’-monophosphate (cGMP) 
that acts as a second messenger through a variety of enzymatic reactions. ese 
reactions may involve protein kinases, phosphodiesterases (PDE), or modulation 
of ion channels, leading to the effects generated by NO, e.g. relaxation of smooth 
muscle or inhibition of platelet aggregation. In host defence reactions the 
mechanism of action is not thought to be mediated through cGMP pathways. 
Instead intracellular iron loss and inhibition of mitochondrial respiration and 
DNA synthesis has been suggested (18) (Fig 1). 
 Human NOS genes are located on different chromosomes; nNOS is located on 
chromosome 12, iNOS on chromosome 17 and eNOS on chromosome 7 (19-23). 
ey show a 50-60 % homology, are structurally related to each other and they all 
require dimerisation to become active (24) (Fig 2).
Fig 1. 
Enzymatic formation of NO by the conversion of NOS. 
With special thanks to Katarina Hallén
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1.3 NO in normal physiology of the lower urinary tract
NO has been identified as an important non-adrenergic, non-cholinergic (NANC) 
neurotransmitter in the lower urinary tract where it, among other, participates in 
the micturition reflex (25-27). Normal micturition is characterized by an initial 
drop in urethral pressure, followed by an increased intravesical pressure, resulting 
in emptying of the urinary bladder. It is thought that the drop in urethral pressure 
is caused by NO-mediated smooth muscle relaxation (27-30). In addition, it has 
been suggested that NO might also take part in the relaxation of the striated 
urethral muscle (31, 32). e role of NO on detrusor contractility is still a matter 
of controversy . NOS activity in the detrusor is much lower than in the urethra and 
bladder neck but experimental studies on both human and animals has suggested 
that NO may be involved in bladder relaxation (33, 34). Administration of NOS 
inhibitors decreases bladder capacity and results in hyperactivity of the bladder 
(34). NOSs are also present in the prostate and have been proposed to take part in 
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Fig 2. A schematic picture of the three isoforms of NOS; their chromosome location, gene size, 
mRNA transcript and protein structure.

the regulation of prostatic smooth muscle tone, but are also belived to be involved 
in glandular function and local vascular perfusion in the prostate (35-37). With 
the discovery of its essential role in penile erection and the advent of systemic drug 
therapies for erectile dysfunction targeting the NO–cGMP pathway (sildenafil, 
tadalafil, and vardenafil) (38-40) NO has become widely known to the urologists. 
Prior to the discovery of NO it was known that penile erection was mediated 
through NANC neurotransmission. 1990, Ignarro et al., demonstrated that 
NO was endogenously formed and released from isolated strips of rabbit corpus 
cavernosum upon electrical field stimulation (38). is observation suggested that 
penile erection was mediated by cGMP dependent smooth muscle relaxation in 
the corpora cavernosa in response to neuronal release of NO. e NO-dependent 
signal system required for penile erection involves a complex biochemical pathway 
in which several targets are available for pharmacological manipulation. One of 
these is the PDE-5-enzyme, which converts cGMP to its inactive form. Inhibiting 
PDE-5 increases cGMP concentrations resulting in corporal smooth muscle 
relaxation and augmented penile erection (41, 42).
1.4 Interstitial cystitis
Interstitial cystitis (IC) is a chronic inflammatory disease of the urinary bladder. 
It is characterized by bladder pain, frequency, urgency and dysuria but has no 
pathognomonic findings upon clinical or microscopic evaluation. Several other 
diseases including bacterial cystitis, bladder outflow obstruction, pain syndromes, 
neurological disorders, radiation cystitis and malignancy affecting the bladder, 
can cause similar symptoms. One significant problem with IC has been the lack 
of a globally accepted definition of the disease and therefore epidemiological 
and clinical studies have been difficult to compare. For example, the reported 
incidence of IC varies greatly between Europe and North America (43, 44). To 
facilitate IC research studies the National Institute of Arthritis, Diabetes, Digestive 
and Kidney Disease (NIDDK) defined specific criteria for the diagnosis of IC in 
1988 (45). ese criteria were based on exclusion criteria rather than inclusion 
criteria. e National Institutes of Health Interstitial Cystitis Data Base study later 
demonstrated that a strict application of the NIDDK criteria might miss more 
than 60% of patients likely to have IC (46). is led to the consensus that these 
criteria are too strict and should be used only in research settings. e perception 
that the original term, interstitial cystitis, did not encompass the majority of cases 
of the clinical syndrome led to the reevaluation of the nomenclature. e name 

of this disease has therefore undergone repeated revision, first to painful bladder 
syndrome (PBS) /IC introduced by the International Continence Society (47) 
and in 2008 the European Society for the Study of Interstitial Cystitis (ESSIC) 
proposed a change to bladder pain syndrome (BPS) and suggested that the 
diagnosis should be made on the basis of chronic bladder pain plus at least one 
other urinary symptom such as frequency or the urge to void, and that other 
diseases that could cause the same symptoms were excluded (48). e disease will 
be referred to as BPS/IC in the following text in this thesis. Traditionally, BPS/IC 
patients are divided into two subgroups, those with a classic or ulcerous form of 
BPS/IC and those with a non-ulcerous form, with about 90% having the latter 
form. e two subgroups differ in both clinical presentation, age distribution, 
histopathological and neuropathological features as well as in response to different 
treatments supporting the assumption of two different entities of BPS/IC (49-52). 
Patients with ulcerous BPS/IC present with a chronic destructive inflammation, 
mucosal ulcerations named Hunner’s lesions and a decreased bladder capacity. At 
the end stage of the disease they develop a fibrotic bladder with minimal capacity 
resulting in severely comprised quality of life. Patients with non-ulcerative disease 
tend to be younger at diagnosis and signs of inflammation are scant, and the end 
stage with fibrotic bladder does not occur.
1.4.1 Aetiology
Although described for more than a 100 years ago (53) the aetiology and 
pathogenesis of BPS/IC has yet to be elucidated. rough the years extensive 
efforts have been made to establish the pathogenesis behind this disease and several 
theories have been put forward including inflammatory processes (54-56), infection 
(57), urothelial defects and damage to the protective glycosaminoglycan layer in 
the bladder (58, 59), immunological processes such as allergies and autoimmune 
mechanisms (60-62), hypoxia (63) and genetic susceptibility (64). In BPS/IC 
an increased mast cell count in the bladder wall has been found, particularly in 
the ulcerous form of BPS/IC. Mast cells are thought to play a pivotal role in the 
pathology of BPS/IC since they harbour a variety of inflammatory mediators that 
can cause several of the symptoms and histological findings in ulcerous BPS /IC 
such as pain, frequency, oedema, fibrosis and the production of new blood vessels 
in the lamina propria (65-71).

1.4.2 Diagnosis
e diagnosis of BPS/IC is often challenging since the symptoms can be caused 
by several other diseases e.g. carcinoma in situ (CIS). According to the ESSIC 
the diagnosis of BPS/IC in patients with chronic bladder pain (>6 months) 
accompanied by at least one other urinary symptom is based on clinical 
evaluation, physical examination, urine culture, residual urine, information 
on voiding patterns and cystoscopy with bladder distension and biopsies (48). 
Cystoscopic features that are accepted as positive signs for BPS/IC are Hunner’s 
lesions or glomerulations after hydrodistension of the bladder. Biopsies are mainly 
performed to rule out malignancies such as CIS of the urothelium but can also 
provide information on histopathological features common in BPS/IC. e 
ESSIC has proposed that positive biopsy findings are inflammatory infiltrates, 
granulation tissue, mastocytosis and intra-fascicular fibrosis (48). On the basis of 
cystoscopy and biopsy findings sub classification of BPS/IC is possible (Fig 3).
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Fig 3. Diagnosis and sub-classification of BPS/IC. Based on the findings on cystoscopy and 
biopsies subclassification is possible. Positive findings on biopsy are inflammatory infiltrates, 
granulation tissue, mastocytosis and intra-fascicular fibrosis. Adopted from the ESSIC proposal 
(van de Merwe et al. Eur Urol. 2008 Jan;53 (1):60-7).

As for the role of cystoscopy and hydrodistension, views have been divided. 
Interestingly, a study by Zermann et al., in 1999, found petecial hemorrhages in 
patients undergoing sterilization in whom hydrodistention was performed. None 
of these patients showed any symptoms of BPS/IC (72).
1.4.3 Treatment
Treating BPS/IC is a great challenge when managing patients with this disease. 
e one symptom most difficult to control in these patients is the pelvic pain, 
which is thought to have nociceptive, visceral and neuropathic components. 
Several different treatment modalities are being used in clinical practice including 
both oral and intravesical treatment with pharmacological agents as well as 
surgical approaches. 
 e original two types of BPS/IC respond differently to treatments and a 
correct sub classification is essential when choosing therapy. For example patients 
with non-ulcerous BPS/IC do not respond well to reconstructive surgery by any 
method (73).
1.4.3.1 Oral drug treatment
Traditional pain treatment using non-steroidal anti-inflammatory drugs and 
opioids have been found to be ineffective or with limited success (74) and should 
be limited to patients awaiting further treatment. Since the number of mast cells 
have been shown to be increased in bladder biopsies from several patients with 
BPS/IC (56) antihistamines have been tried in BPS/IC treatment, although a 
randomized trial involving hydroxyzine failed to show a significant advantage 
compared to placebo (75). Amitriptyline is commonly used for the neuropathic 
component of pain seen in these patients and is recomended by the European 
Association of Urology (EAU). Pentosan polysulfate sodium (PPS) is another 
frequently used oral agent in treating the symptoms of BPS/IC. It is an oral 
heparinoid that is thought to augment the protective glucosaminoglycan layer of 
the bladder and was originally described in 1990 for the use of IC treatment (76). 
However, this treatment seems to improve urinary frequency more than pain (77). 
Glucocorticoids are potent anti-inflammatory drugs affecting the production of a 
wide range of inflammatory mediators and already in 1953 it was reported to have 
a temporary improvement of symptoms in patients with BPS/IC (78) but is not 
recommended by the EAU in their treatment arsenal (79). Immunosuppressive 
treatment with cyclosporine has been shown to possess superior effect to PPS in 

randomized controlled trials but also has more side effects (80-82).
1.4.3.2 Intravesical drug treatment
Intravesical dimethyl sulfoxide (DMSO) was already in 1967 reported to improve 
BPS/IC symptoms by 75% (83) but more recent trials have not entirely been able 
to confirm this effect. Although 93% of the patients in a study from 1998 showed 
an improvement of symptoms the same study revealed that 59% relapsed in the 
following four weeks (84). Also intravesical PPS is commonly used.
1.4.3.3 Surgical treatment
Hydrodistension of the bladder is not only used as a diagnostic tool for BPS/IC 
but is also used in the treatment of BPS/IC. e mechanism of action is believed 
to be caused by damaging the submucosal neuronal plexa due to the mechanical 
stretch of the bladder wall. is, in turn, would thereby decrease pain transmission 
through the afferent fibers. e effect of the therapy range from 12-70% but the 
effect has been reported to be brief, with a duration of 3-6 months (85, 86). It is 
also possible to perform transurethral resection of the Hunner’s lesions following 
bladder distension (87). As the disease progresses more radical surgery may be 
required, such as bladder augmentation and urinary diversion, although the 
success rate following surgery varies substantially between different series (25-
96%) (88). In a recent study by Rössberger et al., it was shown that only patients 
with the ulcerous form of BPS/IC benefit from this kind of reconstructive surgery 
making it crucial to obtain a correct sub classification (73).
1.5 NO in bladder pain syndrome/interstitial cystitis
As already mentioned, NO is an objective marker for detecting inflammation (8, 
9) and can be used in the diagnosis of classic BPS/IC. In patients with bladder 
inflammation luminal levels of NO are significantly increased compared to 
patients without inflammation of the bladder (10, 11). It is also possible to identify 
BPS/IC patients with classic ulcerous IC since they show increased endogenous 
formation of NO in the urinary bladder, which is not the case in the non-ulcerous 
form (89). is allows sub classification without performing hydrodistension and 
biopsies. 
 Measuring NO in the bladder is a relatively simple technique with few 
complications. It can also be used in the objective evaluation of different 
treatments. Hosseini et al., reported a decrease in luminal NO in the urinary 

bladder after treatment with steroids for classic BPS/IC and that the decrease in 
NO correlated to a decrease in symptom score in the same patients (90). 
NOS activity has been shown to be up regulated in the urothelium during bladder 
inflammation and it is therefore likely that the NO measured in the bladder from 
patients with BPS/IC originates from the bladder mucosa. However, it is possible 
that inflammatory cells in the bladder wall contribute to the luminal NO measured 
in patients with BPS/IC. Since NO has a very short half-life in biological tissues, it 
is not likely that NO produced deeper in the bladder wall would contribute to the 
rise in bladder luminal NO.
 Whether elevated levels of NO are part of the pathogenesis in BPS/IC or simply 
a part of a secondary inflammatory response is yet to be elucidated. 
1.6 Urinary Bladder cancer
Urinary bladder cancer is the ninth most common cancer worldwide, both sexes 
combined (91) with a male to female 3:1 ratio (92). In Sweden it is the sixth most 
common cancer form responsible for 4.5% of all new cancers. e incidence 
increases with age and is rare in individuals under the age of 45. Ninety percent 
of the bladder cancer cases are transitional cell carcinomas but squamous cell 
carcinomas and adenocarcinomas may also occur. Smoking is a well-established 
environmental risk factor for developing bladder cancer (93, 94), which is also 
the case with aromatic amines that commonly occur in iron and aluminium 
processing, industrial painting and printing (95). For squamous cell carcinoma of 
the bladder, infection with Schistosoma haematobium is the most common cause 
(96). Bladder cancer is not a hereditary disease but patients with a family history 
of bladder cancer have a slightly increased risk for disease development (97). Since 
not every patient with exposure to risk factors develop urinary bladder tumours 
and since some patients without risk factors develop the disease, it is evident 
that other factors than environmental influence the risk of cancer development. 
is could be caused by gen-environment and gene-gene interactions. It is also 
possible that this susceptibility can be caused by variations in DNA sequences e.g. 
polymorphisms. 
 Approximately 75-80% of the tumours present as non-muscle invasive bladder 
cancer (NMIBC) confined to the mucosa (Ta or CIS) or submucosa (T1). e 
remaining 20-25% consist of tumours invading the detrusor muscle or beyond 
(98) (Fig 4). For staging and grading, the tumour-node-metastasis (TNM) 

classification is used together with the World Health Organisation (WHO) 
histological grading systems from 1973 and 2004 (99, 100). e recurrence rate for 
NMIBC is approximately 65% but only 10% progress to muscle invasive disease 
(101), with the exception of CIS. CIS is a flat, high grade, non-invasive lesion that 
may occur as a primary lesion in 1-4% of all bladder cancers, or concomitant with 
a papillary tumour in 13-20 percent of all bladder cancer patients (102, 103). Left 
untreated, CIS has a high risk of progression to invasive disease; approximately 
50% of patients with untreated CIS develop invasive growth within 5 years (103, 
104), and when occurring concomitantly with a high-grade pT1 papillary tumour, 
the risk for progression is even higher (105). Patients with muscle invasive tumours 
at diagnosis are more likely to progress despite radical surgery, radiation and/or 
chemotherapy (101).
 e diagnosis of bladder cancer is based on cystoscopic findings in combination 
with urinary cytology and histopathological examination of transurethral resection 
specimens or biopsies. e choice of treatment depends on several factors including 
stage, grade, the presence of a metastasis (distant or nodal) in combination with 
the general physical condition of the patient. For muscle invasive tumours, radical 
cystectomy with or without neo-adjuvant chemotherapy is the treatment of choice 
Fig 4. Staging of bladder tumours.
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provided that no metastases are present at diagnosis. When treating NMIBC 
it is important to establish the risk for recurrence and progression to optimize 
treatment results and avoid unnecessary over treatment. For this, the EAU has 
developed scoring systems and risk tables (Table 1). It is recommended in the 
EAU guidelines for NMIBC (98) to give an immediate intravesical instillation 
with a chemotherapeutic agent following the first transurethral resection to 
all patients. is is not the case in Sweden where post-operative instillations 
following the firs resection are not advocated in national clinical guidelines, but 
there are variations in clinical practise. In patients with low risk of recurrence and 
progression no additional treatment is recommended except for the initial post-
operative instillation of chemotherapy. In patients with intermediate or high risk 
of recurrence and in intermediate risk of progression the immediate instillation 
of chemotherapy should be followed by further instillations of chemotherapy or 
maintenance with Bacillus Calmette-Guérin (BCG). In patients with high risk 
for progression BCG with maintenance for at least a year is indicated following a 
first initial chemotherapy instillation. It is also reasonable to propose immediate 
cystectomy to patients with NMIBC at high risk of progression.
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Table 1. Scoring system and risk table for NMIBC provided by the EAU 
(Babjuk et al. Eur Urol. 2008 Aug;54(2):303-14)
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1.7 NO in Tumour biology and especially in bladder cancer
Tumour growt h depends on various factors such as the properties of the tumour 
cells and their interaction with endothelial cells and tumour infiltrating immune 
cells (106). All of these cell types have been shown to produce NO in vitro (4, 6, 
18, 107, 108). Several human cancers express iNOS (109, 110) suggesting that NO 
may be produced in tumour tissues. is opens for the possibility that NO could 
take part in tumour development and progression. Also bladder tumours have been 
shown to express iNOS in the urothelium (111) and in vitro studies have shown 
both calcium dependent and calcium independent NOS activity in both murine 
and human bladder cancer cell lines (MBT-2 and T24) (112). Diverging results 
on the role for NO in tumour biology have been reported. In some studies, NO 
seem to enhance tumour cell proliferation and angiogenesis (113) and, in others, 
increased NOS activity appears to correlate to a diminished metastatic ability 
(114). Other studies have reported that NO had no apparent effect on tumour 
growth (110). eNOS expression has been demonstrated in the endothelium of 
bladder tumour vessels (115) and endothelial derived NO, produced by eNOS, has 
been proposed to promote angiogenesis and cancer invasiveness (115, 116).
 Endogenous NO production may influence cell growth and in 1995 omae 
et al., described a dual effect of NO on endothelial cell growth (117). It was noted 
that low concentrations of NO stimulated cell growth and high concentrations 
inhibited cell growth. In vitro studies on bladder cancer cells have suggested a 
similar role for NO in bladder cancer, promoting cell growth when produced at 
low concentrations whereas high concentrations result in cytostatic and cytotoxic 
effects (112, 118). Cytokine treatment of bladder cancer cell lines resulted in 
induction of calcium independent NOS activity with growth arrest and apoptosis 
as a result. When adding a NOS inhibitor apoptosis did not occur, suggesting that 
NO pathways are involved in this process (112, 118).
1.8 BCG treatment for bladder cancer
1.8.1 The history of BCG
In 1908 two researchers at the Pasteur Institute in France, Albert Calmette and 
Camill Guerin, began their pioneering work in searching for a vaccine against 
tuberculosis (TB) and in 1921 the vaccine was first tested in a human (119). e 
vaccine was named Bacillus Calmette-Guérin (BCG) and is a live, attenuated 
substrain of Mycobacteria Bovis. In the early 20th century, TB was noted to have 
antitumor effects. In an autopsy study from 1929, Pearl reported a lower frequency 

of cancer in patients with TB. He also noted that patients surviving malignancies 
had higher incidence of active or healed TB (120). ese observations encouraged 
researchers in their quest to use BCG as an anti tumour agent, and in the late 
1950s BCG was found to activate macrophages and having the capacity to destroy 
cancer cells in mouse tumours (121). In the beginning of the 70ties, pioneering 
results on BCG as an effective cancer treatment (122, 123) generated enormous 
interest followed by several clinical studies, but BCGs promise as an effective anti 
tumour agent was not fulfilled with one notable exception, in bladder cancer. In 
1976, Morales et al., developed a schedule for effectively treating non-muscle 
invasive bladder cancer (124). Although BCG is regarded the most successful 
immunotherapy agent for bladder cancer to date, its mechanism of action remains 
largely unknown. As reviewed by Brandau in 2007 (125), mycobacteria following 
BCG instillation are internalized into the urothelial cells after adherence to 
fibronectin. Proinflammatory cytokines are then secreted by the urothelial cells 
and act as chemotactants and attract innate immune cells e.g. neutrophiles and 
macrophages which further enhance the local production of cytokines and 
chemokines. e result is a strong non-specific inflammatory reaction with a 
1 response with activated cytotoxic T-cells and natural killer (NK) cells which 
together with macrophages are thought to eradicate bladder tumour cells (Fig 5). 
Fig 5. Attenuated mycobacteria (BCG) is internalized into the urothelial cells and antigene 
presenting cells (APC). Proinflammatory cytokines produced by the urothelial cells attract 
neutrophiles and macrophages, which will further enhance the 1 response and the activation 
of cytotoxic T-cells and NK-cells, resulting in tumour eradication.
NK-cellCytotoxic T-cellMacrophageNeutrophileAPCUrothelial cellBCG
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1.8.2 BCG treatment for bladder cancer
Treatment with BCG infused directly into the bladder is the most effective 
adjuvant intravesical treatment for preventing recurrence of NMIBC and is 
the golden standard for treating CIS (126). Although being a very effective 
treatment, not all patients with NMIBC should be treated with BCG due to 
their favourable prognosis and the risk for BCG toxicity. In patients with low 
risk of recurrence and progression, BCG may be considered overtreatment. In 
the EAU guidelines for NMIBC (98) BCG is recommended in patients at high 
risk of tumour progression, and is to be given after one immediate instillation 
of chemotherapy for at least one year. BCG can also be considered in patients 
with an intermediate or high risk of recurrence and an intermediate risk of 
progression. Also in this setting BCG is recommended after one immediate 
instillation of chemotherapy and should be given as maintenance for at least 
one year but other intravesical agents given as maintenance can also be used. 
To establish the risk for recurrence and progression in NMIBC and thus making a 
risk assessment the EAU has developed scoring systems and risk tables (Table 1).
 BCG is given as an induction course with one instillation weekly for six weeks 
and should be followed by maintenance for at least one year (98). e optimal 
frequency, number of instillations and duration of maintenance BCG therapy has 
not been established. ere are several local differences in treatment protocols 
between countries and even within countries. 
 Not all patients respond to BCG treatment, 30-35 % either relapse within the 
first five years after treatment or fail to respond entirely (127). Patients with high-
risk NMIBC undergoing conservative treatment with BCG, should therefore 
be followed closely for early detection of BCG failure and subsequent disease 
deterioration. If signs of BCG failure are found radical surgery is the treatment of 
choice. e observation that radical surgery in BCG non-responders may have a 
less favourable prognosis than those undergoing immediate cystectomy (128), call 
for the identification of prognostic markers for those at risk for BCG failure.
1.9 NO in BCG treatment for bladder cancer
Elevated levels of NO have been reported in the bladder after BCG treatment 
(118, 129) and this increase in NO levels is seen after the first treatment and is 
sustained for up to six months. In vitro studies have revealed that several of the 
cytokines excreted in urine following BCG instillations (130, 131) are capable of 
evoking NO synthesis and NOS activity in both normal and urothelial tumour 
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cells with growth arrest and apoptosis as a result (112). When adding a NOS 
inhibitor apoptosis did not occur, suggesting that NO pathways were involved 
in this process (118). Furthermore, the application of NO donors may have an 
anti-proliferative effect on bladder cancer cells in vitro (112). is is in line with 
other studies which have detected iNOS protein and NOS activity in the bladder 
mucosa after BCG treatment (132). e mechanisms through which NO exerts 
its cellular cytotoxic effects have been attributed to intracellular iron loss with 
inhibition of mitochondrial respiration (1), inhibition of DNA synthesis by 
inhibiting ribonucleotide reductase activity (133), DNA strand breaks through 
nitrosylation of nucleic acids (134, 135) and a direct interaction with nuclear DNA 
causing DNA damage and mutations (135). Whether NO plays a role in the anti 
tumour activity that BCG exerts on tumour cells or is merely a response to the 
inflammatory reaction warrants further investigation.
1.10 Polymorphisms
A polymorphism is an inherited genetic variation in the base sequence of DNA co-
existing in a population with a frequency >1%, and the polymorphism is present 
in every cell of an individual. Normally polymorphisms are not associated with 
severe diseases (136) and polymorphisms are common throughout the genome and 
can occur in both introns and exons. Single nucleotide polymorphism (SNP), the 
most common type of polymorphism, can occur as frequently as 1 per 300 base 
pairs (137). In every cell two alleles of a gene exist (one from the mother and one 
from the father). e most frequently occurring genetic variant in a population is 
considered common/normal and named the wild-type allele and the other alleles 
that are represented by fewer individuals in the population are called rare or 
variant alleles. Since the frequency of an allele varies in different populations the 
normal allele is population specific (Fig 6). 
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Fig 6. A SNP in the DNA can cause a change of an amino acid. 
With special thanks to Charlotta Ryk.
 Polymorphisms that occur within an enzyme may influence the enzyme activity. 
If the enzymes take part in processes involving cell cycle control, DNA repair 
mechanisms or the metabolism of toxic substances and medicines, the carriers of 
a variant allele might have a different susceptibility to disease development and 
to drug response. For example, a number of studies have shown an association 
between the medical outcome of a treatment and polymorphisms (138-140) 
and cancer risk has also been associated to different polymorphisms (141-145). 
However, it is important to keep in mind that the effect of a single polymorphism 
is normally modest in an individual, but may be rather significant on a population 
level. 
1.10.1 Polymorphisms and cancer
e development of a cancer involves several steps including a promotion step, 
which may be initiated by a mutation that could increase genetic instability 
with the risk of further genetic alterations. Furthermore, the cancer cell has to 
gain properties that can allow it to proliferate independent of normal growth 
stimulation, acquire resistance to apoptosis, enable it to stimulate angiogenesis 
and give rise to the possibility of invading other tissues (146). Both environmental 
and genetic factors as well as gene-environment interactions can be involved in 
the development and progress of a cancer and polymorphisms in these genes can 
affect the susceptibility for developing a cancer. In bladder cancer 31% of the 
cases have been estimated to be caused by heritable factors (147). is suggests 
that low-penetrance genes and their polymorphisms could play an important 
role in bladder cancer, which is closely related to smoking habits and exposure 
to aromatic amines. For example a slow acetylation phenotype for the NAT2 
gene has been correlated to bladder cancer risk in smokers (148). Furthermore, 
polymorphisms in DNA repair and in metabolic genes are associated with p53 
mutations in urinary bladder cancer (149-152).
1.10.2 Polymorphisms in the iNOS and eNOS genes in bladder cancer
iNOS expression has been reported in several cancers including bladder cancer 
(109-111, 115). e iNOS (CCTTT)n promoter microsatellite polymorphism at 
-2,6kb has been suggested to be associated with gastric cancer and bladder cancer 
(153-155). In a recent study by Ryk et al., a long set (13 or more) of (CCTTT)n 
repeats were associated with a lower risk for developing bladder cancer but also 
with a higher risk for disease progression and cancer specific death once cancer had 
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emerged (155). In addition, eNOS polymorphisms have been associated to cancer 
risk and progression (156-160). Ryk et al., has recently found a correlation between 
bladder cancer and both the eNOS promoter polymorphism -786T>C and the 
intragenic eNOS polymorphism Glu298Asp (manuscript under revision in Nitric 
Oxide: Biology and Chemistry).
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AIMS OF THE STUDY
e present work was carried through in order to study the role of nitric oxide in 
lower urinary tract disease. In particular, the following issues were addressed:
• To study whether high levels of endogenously formed NO also 
correspond to increased levels of iNOS at a transcriptional and protein 
level in patients with interstitial cystitis.
• To identify the localization of iNOS in the bladder mucosa in patients 
with interstitial cystitis.
• To analyze endogenous NO formation and iNOS gene expression at a 
transcriptional and protein level in patients with urinary bladder cancer 
of different stage and grade.
• To study the local NO formation and iNOS gene expression at a 
transcriptional and protein level in patients treated with BCG for 
urinary bladder cancer. 
• To identify the localization of iNOS in the urinary bladder after BCG 
treatment for bladder cancer.
• To investigate if NOS2 and NOS3 polymorphisms influence the 
outcome after BCG treatment for bladder cancer.
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MATERIALS AND METHODS
3.1 Study populations (Paper I-IV)
In paper I the study population consisted of 6 patients with classic BPS/IC and 
8 control subjects without disease of the urinary bladder that were scheduled for 
endoluminal extraction for upper urinary tract stones. 
 In paper II NO was measured in 66 patients with transitional carcinoma of the 
bladder, 6 patients who had received BCG treatment and 6 tumour free control 
subjects with stress incontinence. e study population for real time PCR and 
Western blot consisted of biopsies from 28 patients with transitional carcinoma 
of the bladder, 3 patients who had received BCG treatment and 8 tumour free 
control subjects with upper urinary tract stone disease.
 In paper III the study population consisted of 11 patients with bladder cancer 
who had received a six-week induction treatment with BCG and 11 tumour free 
control subjects without disease of the urinary bladder who were scheduled for 
endoluminal stone extraction in the upper urinary tract.
 e study population in paper IV was selected from a population based material 
of 538 patients with a newly diagnosed bladder cancer. is cohort of patients had 
been prospectively collected from hospitals in Stockholm County between January 
1995 and December 1996. Out of these 538 patients venous blood was available 
in 359 patients, and they were genotyped for NOS2 and NOS3 polymorphisms. 
Eightyeight of these patients presented with high-risk NMIBC, e.g. TaG3, T1 or 
primary CIS transitional cell carcinoma and were included in the present study. 
Fortyeight of the patients had received BCG treatment at some point. For these 
patients we have a clinical evaluation with up to 15 years of follow up.
 For more detailed information on the study populations, see the individual 
papers. 
3.2 Tissue collection (Paper I, II and III)
Biopsies from the urinary bladder were obtained during transurethral surgery 
from patients with urinary bladder cancer of different stage and grade, patients 
treated with BCG, patients with BPS/IC and from control subjects without 
disease of the urinary bladder undergoing transurethral surgery for upper urinary 
stone disease. e biopsies were snap frozen in liquid nitrogen and stored at –70oC 
until analyzed. Reagent strip urine analysis for urinary tract infection (UTI) was 
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negative in all patients and control subjects. Biopsies were obtained after informed 
consent and the local ethics committee approved the study protocol.
3.3 RNA extraction and cDNA synthesis (Paper I, II and III)
Total RNA was isolated using the RNeasy Mini Kit according to the 
manufacturer’s instructions (Qiagen®) and quantified by spectrophotometry. Two 
µg of total RNA were used for cDNA synthesis, using either the SuperScript® II 
RT kit (paper I and II) or the Superscript® III First-strand Synthesis SuperMix 
kit (paper III) according to the manufacturer’s instructions (Invitrogen®, Life 
Technologies). 
3.4 Real time Polymerase Chain Reaction (Paper I, II and III) 
Fifty ng of cDNA were amplified by real time PCR with TaqMan universal 
PCR Master Mix (Applied Biosystems, Life Technologies) using 1mM primers 
and 0,5mM probes (Invitrogen® Life Technologies and Applied Biosystems, Life 
Technologies). iNOS primers and probe were custom made and the primers and 
probe for β-actin were purchased as assay on demand. Each patient sample was 
analyzed in duplicate using the ABI Prism 7700 Sequence Detector (paper I and 
II) or the 7900HT Fast Real-Time PCR System (paper III) (Applied Biosystems, 
Life Technologies). e PCR amplification was correlated against a housekeeping 
gene, β-actin, and all samples were analyzed in either a singleplex reaction with 
iNOS and β-actin in different wells or in a multiplex reaction with iNOS and β-
actin amplified in the same well.
 In paper I and II iNOS was quantified using a standard curve. In paper III 
the number of iNOS PCR cycles, e.g the CT-values, needed to detect iNOS 
expression was divided with the CT value for β-actin in each patient, and the 
difference between groups were calculated using the ΔΔCT method for relative 
comparison.
3.5 Western Blot (Paper I, II and III)
Frozen biopsies were pulverised in liquid nitrogen using a Braun Mikro-
Dismembranator and then lysed in a modified RIPA buffer. e lysate was 
then centrifuged at 10.000 x g for 10 min at 4oC. e protein content of the 
supernatant fluid was determined with the Bradford protein assay according to the 
manufacturer’s instructions (Bio-Rad Laboratories).
Equal amounts of protein from each sample was loaded onto a protein gel and 
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separated under reducing conditions by electrophoresis. Proteins were then 
transferred onto PVDF membranes (Bio-Rad Laboratories) using wet transfer and 
then blocked for one hour. e membranes were probed over night with either 
a mouse anti-human iNOS antibody (BD-Biosciences) or a mouse anti-human 
IgG1 β-actin antibody (Sigma-Aldrich). e membranes probed for iNOS was 
consecutively incubated with an anti-mouse biotinylated antibody followed by an 
anti-biotin-HRP antibody and the membranes probed for β-actin was directly 
incubated with an anti-mouse-HRP antibody. Blots were then developed with 
Western Blot detection reagents and photographed.
3.6 Immunohistochemistry (Paper I and III)
Biopsies were sliced in a cryostat in sections of 10µm and fixed in acetone. e 
sections were incubated with a rabbit polyclonal antibody raised to human iNOS 
(Santa Cruz Biotechnology, Inc.) and incubated over night at 4oC. To identify the 
inflammatory cells a mouse polyclonal antibody raised to human CD16 (Santa 
Cruz Biotechnology, Inc.) was also added. e sections were then rinsed and 
incubated for one hour with a goat anti rabbit antibody labelled with ALEXA 
Fluor 488 (Invitrogen®, Life Technologies) and a goat anti mouse antibody labelled 
with ALEXA Fluor 594 (Invitrogen®, Life Technologies) to identify iNOS and 
CD 16. e sections were mounted in Keisers glycerol gelatine (Merck). All 
micrographs of the immunolabeled sections were obtained using a digital camera 
system (Nikon microscope and camera), using appropriate filter settings for 
ALEXA Fluor 488 and ALEXA Fluor 594.
3.7 NO determinations in human urinary bladder (Paper I-III)
e NO concentration was measured by introducing a 100% silicon catheter 
into the bladder and then infusing 25mL room air into the catheter balloon. 
After 5 minutes incubation, the air was aspirated into a syringe and peak levels 
of NO were measured using a chemiluminescense NO analyzer (CLD 700, Eco 
Physics, Dürnten, Switzerland). Air from the examination room was also collected 
and analyzed in order to determine the NO concentration in the bladder by 
subtracting the NO level in the room air from the peak value in the air incubated 
in the catheter balloon. e detection limit for NO was 1 ppb and the analyzer 
was calibrated at known concentrations of NO in N
2
, using an electromagnetic 
controller. 
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3.8 Genotyping methods (Paper IV)
3.8.1 Fragment analysis
PCR primers were designed with Primer3 software (http://(frodo.wi.mit.edu) 
and the forward primer was labelled with 6FAM™. PCR products were generated 
using 0.3 µM primer, AmpliTaq Gold® PCR buffer, MgCl2, DTP, and AmpliTaq 
Gold DNA polymerase (AppliedBiosystems). 1 µl of the PCR product was mixed 
with Hi-Di™ Formamide (AppliedBiosystems) and GeneScan™ 500 LIZ® Size 
Standard (AppliedBiosystems), heated for 3 minutes at 95° C, cooled on ice and 
analyzed using ABI Prism® 3730 Genetic Analyzer (AppliedBiosystems). Primary 
data were analyzed with GeneMapper®, version 4.0. 
3.8.2 Allelic discrimination assay
TaqMan primers and probes were purchased from AppliedBiosystems and PCR 
was performed according to the manufacturers instructions, using 10ng DNA as 
template. e genotyping of amplified PCR products was scored by differences in 
VIC and FAM fluorescent levels in plate read operation on ABI PRISM 7900HT 
sequence detection system (AppliedBiosystems) using SDS-2.2.1 software. 
3.8.3 DNA sequencing
Sequencing was used as quality control to verify authenticity of amplified 
sequences. ExoSAP-IT (GE Healthcare) treated PCR products, together with 
sequencing primer were added to the 5µl sequencing reactions, performed with 
BigDyeR Terminator Cycle sequencing kit (AppliedBiosystems), according to 
manufacturer’s instructions. Sequencing reaction products were treated with 
BigDye XTerminator and loaded onto an ABI prism 3730 Genetic Analyzer 
(AppliedBiosystem). e data were analyzed using Sequencing Analysis 5.2 
software (AppliedBiosystems) and 4Peaks. 
3.9 Statistics (Paper I-IV)
In paper I and III the Mann-Whitney U-test for unpaired comparisons was used 
for statistical significance. Data was analyzed with a statistical software package 
(Sigma Stat). 
 In paper II two-tailed statistical significance were determined by comparison of 
mean values with analysis of variance (ANOVA) and for analyses with only two 
variables Students’ t test for unpaired data was used. Data was analyzed using the 
same statistical software package as in paper I and III (Sigma Stat). 

 In paper IV all calculations were done with IBM SPSS Statistics, version 19.0 
(IBM SPSS®). To assess the risk of cancer specific death and tumour progression 
over follow-up time we estimated hazard ratios (HR) using the Cox proportional 
hazards model. Plots of the Kaplan-Meier estimator with the two-sided log rank 
test were used to visualize the cumulative effect of polymorphisms over time.
 For more detailed information on the experimental procedures, see the 
individual papers.
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RESULTS 
4.1 NO in PBS/IC (paper I)
In bladder biopsies from patients with classic BPS/IC we found an increased iNOS 
expression at both transcriptional and protein levels compared to controls. is 
corresponded to high levels of endogenously formed NO in the same patients. 
 Using real-time PCR iNOS expression at a transcriptional level was 
detected in all biopsies, including those from control subjects. iNOS 
mRNA expression was significantly higher in biopsies from patients with 
BPS/IC as compared to control subjects (14.2x10-3 ± 9.2x10-3 vs 2.0x10-3 
± 1.1x10-3, p>0.01, Fig 7). Compared to controls endogenously formed NO 
was significantly increased in the urinary bladder in patients with PBS/IC 
(284 ± 218 vs 2 ± 1 ppb, p<0.001, Fig 7).
 Biopsies from both controls and patients with BPS/IC were also examined with 
Western Blot technique for iNOS protein expression. iNOS protein expression 
was found only in biopsies from patients with BPS/IC, (Fig 7). 
 For iNOS localization in the bladder wall, immunohistochemistry was 
performed on bladder biopsies from the two groups. is showed a strong 
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Fig 7. (A) ere was significantly higher endogenously formed NO in patients with PBS/
IC vs controls, p<0.001 (B) Real-time PCR shows that mRNA expression for iNOS was 
significantley higher in patients with PBS/IC, p<0.01. (C) iNOS protein expression in biopsies 
from patients with BPS/IC and controls with normal bladder mucosa. RAW264.7 mouse 
macrophages stimulated with LPS and interferon γ served as positive control for iNOS protein 
expression.
A B C
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immunolabeling of the urothelium in patients with BPS/IC compared to healthy 
controls (Fig 8). iNOS immunoreactivity in patients with BPS/IC was also found 
in inflammatory cells both in the submucosa and in the urothelium (Fig 8).
4.2 NO in urinary bladder cancer (paper II)
In this study we found an increase in mRNA expression and protein levels for 
iNOS as well as elevated levels of endogenously formed NO in patients with CIS 
compared to patients with papillary tumours and healthy controls. No differences 
in NO production or iNOS gene and protein expression were seen in patients 
with papillary transitional cell carcinoma, regardless of stage and grade. Primarily 
our data showed increased NO production in GIII tumours compared to GI-GII 
tumours but further stratification showed that these augmented levels of NO 
production were found in patients with CIS lesions (alone or with a concomitant 
papillary GIII tumour).
 Using real-time PCR mRNA expression was quantified in patients with bladder 
cancer of different grade and stage. No statistically significant differences were 
found between GI tumours (2.4 x 10-5 ± 0.8 x 10-5), GII tumours (1.8 x 10-5 ± 0.6 
x 10-5) or GIII tumours (9.2 x 10-5 ± 5.6 x 10-5) p=0.07, although data indicated 
an increase in mRNA expression in GIII tumours (Fig 9). However, we observed 
significantly higher iNOS mRNA levels in biopsies from CIS lesions (15.3 x 10-5 ± 
9.9 x 10-5) and they accounted for the difference seen in iNOS mRNA expression 
in GIII tumours (Fig 9). Tumour stage had no impact on iNOS mRNA expression 
in our study. e same observation was made when analyzing local NO production 
in the urinary bladder in patients with bladder cancer. NO concentrations were 
higher in patients with GIII tumours (12 ± 4 ppb) as compared to patients with 
GII (2 ± 1 ppb), GI tumours (2 ± 1ppb) and controls (3 ± 1ppb) p<0.01, (Fig 9). 
Fig 8. Immunohistochemistry for iNOS in bladder biopsies from patients with BPS/IC (B-D) 
and a control subject (A). In picture B-D double immunolabeling for iNOS (red fluorescence) 
and the macrophagemarker CD16 (green fluorescence) show the co-localization of iNOS and 
iNOS expressing macrophages in the bladder wall, as indicated by arrows.
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As with iNOS mRNA expression, patients with CIS alone or with a concomitant 
papillary GIII tumour, accounted for the increase in luminal NO seen in patients 
with a GIII tumour. When data was divided into two groups, one with CIS and 
one with papillary GIII tumours without concomitant CIS, the NO levels found 
in patients with papillary tumours without concomitant CIS were the same as for 
GI and GII tumours (3 ± 1ppb, Fig 9).
 ree patients treated with BCG for bladder cancer were also investigated 
for iNOS mRNA and protein expression as well as for endogenously 
Fig 9. (A) ere was a significantly higher level of endogenously formed NO in patients with 
GIII tumours compared to GI–II tumours and control subjects. (B) Patients with CIS lesions 
(alone or concomitant with a GIII papillary tumour) had significantly higher levels of NO 
compared to patients with papillary bladder tumours regardless of grade (GI–GIII). ere was 
a significantly higher level of NO in patients treated with BCG as compared to all other groups. 
(C) iNOS gene expression did not differ in biopsies from bladder tumours of different grade 
(GI–GIII), normal bladder mucosa in patients with bladder tumours and control subjects. (D) 
ere was a significantly higher level of iNOS mRNA in biopsies from CIS lesions as compared 
to biopsies from papillary bladder tumours of different grade (GI–GIII), normal mucosa in 
bladder cancer patients and control subjects. In biopsies from BCG treated bladder cancer 
patients there was a significantly increased iNOS gene expression as compared to all other groups. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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formed NO. BCG treated patients showed markedly increased levels of NO 
(716 ± 409 ppb) and mRNA expression (27.4 x 10-5 ± 5.7 x 10-5) in the bladder, 
(Fig 9). Biopsies were also examined for iNOS protein expression using Western 
Blot. is demonstrated higher iNOS protein expression in biopsies from CIS 
lesions and patients treated with BCG, thus confirming the PCR results. 
4.3 NO in BCG treatment for bladder cancer (paper III)
In this paper we studied 11 patients with urinary bladder cancer who had received 
a six-week induction treatment with BCG and 11 tumour free control subjects. 
Luminal NO was measured in all patients (386 ± 245 ppb) and control subjects (2 
± 1 ppb) and there was a significant difference between the two groups, p<0.001 
(Fig 10). With real-time PCR mRNA levels for iNOS were investigated and 
showed detectable levels in both control subjects and BCG treated patients but 
there was a ten-fold increase in iNOS mRNA expression in the BCG treated 
patients compared to control subjects (Fig 10). 
 iNOS protein expression was evaluated with Western Blot and iNOS protein 
was found in the BCG treated patients (Fig 10). ese data are well in line with 
Fig 10. (A) Endogenously formed NO in urinary bladders from patients with BCG treated 
bladder cancer and control subjects. ere was a significantly higher level of NO in patients 
treated with BCG as compared to control subjects (p<0.001). (B) iNOS transcriptional 
expression in biopsies from BCG treated bladder cancer patients and control subjects as 
measured by real time PCR. In biopsies from BCG treated bladder cancer patients there was 
a significantly increased iNOS gene expression as compared to control subjects (p<0.003). (C) 
Protein expression of iNOS in biopsies taken from patients with BCG treated bladder cancer 
and control subjects. iNOS protein expression was found in cancer patients who had received 
BCG treatment (BCG). LPS and INFγ stimulated RAW cells served as positive control for 
iNOS.
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our the results regarding NO levels and iNOS expression in BCG treated patients 
published in paper II.
 Furthermore, we used immunohistochemistry to study the location of iNOS 
within the bladder wall. We found strong immunolabeling for iNOS in the 
urothelium of patients treated with BCG compared to control subjects. e 
iNOS immunostaining was most prominent in the umbrella cells but also in the 
cell layer closest to the basal membrane (Fig 11). In BCG treated patients iNOS 
immunoreactivity was also found in inflammatory cells in the submucosa of the 
bladder wall. e inflammatory cells were located in submucosal clusters but were 
also found individually close to the basal membrane of the urothelium (Fig 11). 
4.4 NOS polymorphisms and BCG treatment  (paper IV)
In this study we investigated whether polymorphisms in the iNOS/NOS2 and 
eNOS/NOS3 genes may influence outcome after BCG treatment in patients with 
high risk NMIBC, e.g. CIS, TaGIII and T1 tumours.
 For the iNOS/NOS2 (CCTTT)n microsatellite promoter (-2.6kb) 
polymorphism we found no significant differences in cancer specific survival 
Fig 11. Immunohistochemistry for iNOS in biopsies from a control subject (A) and patients 
treated with BCG (B-D). iNOS-like immunoreactivity (green fluorescence) was found in the 
urothelial layer and was stronger in the BCG treated (B-D) patients. Double immunolabeling 
of iNOS and the macrophage marker CD16 (red fluorescence) in the consecutive bladder 
sections from a patient who has received BCG treatment (D-F). Arrows show co-localisation 
of iNOS and macrophages in the bladder mucosa (F). Macrophages were located in clusters 
within the submucosa (B and F) but were also found underlying the basal membrane of the 
urothelium (B), as indicated by arrows. In biopsies where the urothelium was detached the 
urothelium showed strong iNOS immunolabeling and iNOS expressing macrophages within 
the urothelium (C).

between BCG treated and non BCG treated patients for those having a long set 
of repeats, (L=13 or more, L-carriers), p=0.593 (Fig 12). In non-L-carriers cancer 
specific survival was significantly improved for those who had received BCG, 
p=0.027, with a lower risk for cancer specific death (HR:0.26; CI:0.05-1.21; 
p=0.086, Fig 12 and Table 2). Regarding disease progression BCG seemed to 
reduce the risk, but this was not enhanced by the polymorphism.
 For the eNOS/NOS3 promoter polymorphism -786T>C (rs2070744) patients 
with the TT genotype responded better to BCG and had a lower HR for the risk of 
cancer specific death if treated with BCG (HR:0.08; CI:0.01-0.68; p=0.020, Fig 
12 and Table 2). Also the risk for disease progression was lower in this genotype 
with a HR:0.14; CI:0.03-0.63; p=0.011 (Fig 12 and Table 2). In patients with the 
CT and TT genotype no advantage regarding cancer specific death and disease 
progression was seen after BCG treatment.
 For the eNOS/NOS3 intragenic polymorphism Glu298Asp (rs1799983) GT 
and TT genotypes showed no difference in cancer specific death and disease 
progression between those who had received BCG and those who had not. 
However GG genotype patients had a lower hazard ratio for stage progression 
if given BCG (HR:0.07; CI:0.01-0.38; p=0.002, Fig 12 and Table 2). e same 
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Table 2. Cancer specific death and disease progression after BCG-treatment. 
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was seen for cancer specific death (HR:0.29; CI:0.07-1.23; p=0.092, Fig 12 and 
Table 2).
Fig 12. Kaplan-Meier analyses for cancer specific survival and disease progression for the  
NOS2 (CCTTT)n polymorphism, the NOS3 -786T>C polymorphism and the NOS3 
Glu298Asp polymorphism. 
For the NOS2 (CCTTT)n polymorphism pair wise comparisons showed a significant difference 
in cancer specific survival after BCG treatment in the non-L-carrier group (p=0.027), but not 
in the L-carrier group (p=0.593). Disease progression was decreased after BCG treatment but 
the (CCTTT)n polymorphism did not influence the outcome after BCG treatment.
For the NOS3 -786T>C polymorphism pair wise comparisons showed a significant difference 
in cancer specific survival and disease progression after BCG treatment in the TT-group, 
p=0.007 and p=0.002 respectively. 
For the NOS3 Glu298Asp polymorphism pair wise comparisons showed a significant difference 
in disease progression after BCG treatment in the GG-group, p<0.001.
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DISCUSSION
Nitric oxide has a variety of functions, both as a signalling molecule and as 
an effector molecule in host defence reactions and in immune regulatory 
processes. High levels of NO are seen in inflammatory diseases and NO 
may have a role in tumour biology. e present thesis mainly focuses on the 
role of NO in BPS/IC pathogenesis and the role for NO in bladder cancer 
biology and its potentially anti-tumour effects following BCG treatment. 
5.1 No in Bladder pain syndrome / Interstitial cystitis
Already in 1996 Lundberg et al., (11) showed that NO formation is increased in 
the urinary bladder in patients with inflammatory diseases and in 2004 Logadottir 
et al., (89) concluded that measuring luminal bladder NO could discriminate 
between patients with the classic form of BPS/IC and those with the non-ulcerous 
form. One of the aims with this thesis was to determine the source of NO and its 
site of production in the bladder mucosa in patients with BPS/IC. 
 Bladder biopsies from patients with BPS/IC and control subjects were 
investigated for iNOS expression with real-time PCR and Western Blot. We 
found that iNOS mRNA expression was increased in BPS/IC patients and that 
protein expression for iNOS was detected in the BPS/IC patients. In addition, 
this corresponded to the elevated levels of endogenously formed NO seen in these 
patients, a finding which in all likelihood is related to the aforementioned iNOS 
mRNA and protein increase. In biopsies from patients with classic BPS/IC the 
immunoreactivity for iNOS was higher in the urothelium compared to control 
subjects suggesting the urothelial cells as a source of the elevated NO levels seen 
in these patients. In addition, strong iNOS immunolabeling was also found in 
immunocompetent cells in the bladder wall, both in the submucosa but also 
within the urothelial layer, which may imply that these cells may also contribute 
to the high levels of NO found in the bladder in patients with BPS/IC. ese 
observations are well in line with findings reported by others demonstrating an 
increased NOS activity in the urothelium and iNOS staining in urothelial cells 
and inflammatory cells in the bladder during inflammation, in both animal 
models and humans (129, 161-163).
 Despite previous efforts researchers have not as yet been able to fully elucidate 
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the aetiology or pathogenesis of this complex disease. In the light of the high levels 
of NO found in patients with classic BPS/IC it is possible that NO may mediate 
some of the pathophysiological events seen in BPS/IC. NO may be harmful when 
produced in excess for a prolonged time due to possible tissue damage caused by 
increased formation of free radicals such as peroxynitrite (164). One important 
factor in BPS/IC pathogenesis is the presumed increase in urothelial permeability 
(58, 165). Excessive iNOS production has been suggested to cause barrier 
dysfunction due to an increase in epithelial permeability in several other tissues 
(166-169). Tight junctions play an important role in epithelial permeability as they 
hold adjacent cells together and act as semi permeable elements. Tight junctions 
are essential for the formation of epithelial sheets, which form an important barrier 
against various noxious substances. In biopsies from BPS/IC patients decreased 
levels of ZO-1 protein, a cytoplasmatic peripheral membrane protein located to 
tight junctions in human bladders was found (170, 171). Furthermore, several 
studies support the notion that iNOS dependent NO production causes epithelial 
barrier dysfunction related to altered expression of the tight junction protein ZO-
1 (166, 169). In some studies this adverse effects on barrier function has been 
attributed peroxinitrite rather than NO itself (172-174). 
 Another role for NO in BPS/IC pathogenesis is the possibility that augmented 
iNOS expression in the bladder wall may be involved in bladder fibrosis, which 
is seen in end- stage classic BPS/IC. It has previously been reported that iNOS 
expression has been related to increased collagen expression (175-179) and in a 
rodent model of pathological fibrosis the inhibition of iNOS activity blocked the 
increase in collagen (180, 181). Furthermore, human bladder smooth muscle cells 
treated with LPS and inflammatory cytokines expressed collagen type III through 
an iNOS dependent pathway (182). 
 In the late nineties therapy with L-argenine was tested in patients with BPS/IC 
with the rationale that patients with BPS/IC had a lower expression of iNOS in 
urine pellets (183). It was suggested that administration of L-arginine to patients 
would increase NO production in the bladder leading to relaxation of the bladder 
and modulation of afferent firing (184). Several similar studies have, however, 
revealed conflicting results (185-188) and the positive effects seen in the first study 
by Smith et al., (184) have not been reproduced. In a study by Korting et al., (185), 
L-argenine had positive effects only in those with a bladder capacity exceeding 
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800ml, and Ehrén et al., (188) showed no positive effect of orally given L-argenine 
to patients with classic BPS/IC who already at the start of the study displayed 
markedly increased NO production. Due to the lack of a proper definition of BPS/
IC patients at that time it is likely that patients in some of the studies consisted of 
both classic and non-ulcerous form of BPS/IC, which could explain some of the 
diverging results. For patients with classic BPS/IC a more rational approach may 
be to pharmacologically decrease iNOS activity and NO production. Bearing in 
mind that NOS inhibitors have anti inflammatory properties in an experimental 
setting (189, 190), iNOS inhibitors may tentatively display beneficial effects also 
in clinical practice. Interestingly, some of the already available drugs for treating 
BPS/IC may exert some of their therapeutic effects through NO/iNOS related 
mechanisms. 
 Cyclosporin A is a calcineurin inhibitor with potent immunosuppressive and 
anti-inflammatory properties (80-82, 191) and has in randomized control studies 
proven effective in the treatment of BPS/IC (80-82). Calcineurin has been shown 
to be required for full iNOS expression in macrophages (192) and it has been 
shown that Cyclosporin A inhibits NO production in macrophages (193-196). 
A recent study by Hämäläinen et al., (197) demonstrated that Cyclosporin A 
down-regulates NO production by destabilising iNOS mRNA. is is in line 
with observations by Ehrén et al., that have shown that endogenously formed NO, 
as measured in the urinary bladder, is decreased during Cyclosporin A treatment 
in patients with classic BPS/IC (personal communication). Also PPS, that can be 
administrated both orally and intravesically in patients with BPS/IC, has been 
implicated to affect the NO/NOS pathway. In a study from 2007, Veszelka et 
al., (198) showed that PPS reversed LPS induced barrier impairment and lowered 
NO levels in brain endothelial cells and that changes in the tight junction 
protein ZO-1 were also reversed by PPS. us, PPS may reverse changes in the 
ZO-1 protein seen in the bladder of patients with BPS/IC (171) thus improving 
bladder impermeability an effect that could be elicited via NO/iNOS pathways. 
DMSO, an intravesical agent for treating BPS/IC, has been attributed a variety of 
mechanisms through which it might exert its beneficial effects in BPS/IC patients. 
For one, DMSO may act through modulation of sensory nerves with a stimulation 
of bladder afferent nerves accompanied by a release of NO and relaxation of the 
bladder (199, 200). is may represent a putative mechanism of action in patients 
with non-ulcerous form of BPS/IC but would probably not cause relaxation and 
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desensitization of nociceptive pathways in classic BPS/IC because of the already 
markedly increased levels of NO produced in the bladder wall of these patients. 
DMSO has also been established as a scavenger for intracellular hydroxyl radicals 
and has also been suggested to be capable of inhibiting peroxynitrite induced DNA 
stand breakage (201) which is one important way through which peroxinitrite may 
elicit cytotoxicity (202).
5.2 Nitric oxide in bladder cancer biology
Evidence for NO involvement in tumour biology has been reported from several 
different forms of cancer both in vitro and in vivo. However, there are conflicting 
reports whether NO promotes or inhibits tumour growth. In some studies it 
appears that NO enhance tumour proliferation and angiogenesis (109, 113, 203) 
while in others an increased NOS activity is correlated to a diminished metastatic 
ability (107, 114) or has no apparent effect at all (110). One way in which NO 
may act tumour promoting has been attributed to its possibility to stimulate 
angiogenesis (113) which is correlated to tumour invasiveness and metastatic 
potential (204). ese diverging results may be due to differences in the rate 
of NO formation and the concentration of produced NO. omae et al., (117) 
described that low concentrations of NO stimulated endothelial cell growth, 
whereas high concentrations acted in an inhibitory fashion. is dual effect of 
NO on cell growth has also been demonstrated in bladder cancer cell lines by 
Morcos et al., (112). 
 In this study iNOS expression was found in biopsies from bladder tumours, 
which is in line with previous reports both in vitro (112) but also in vivo (111, 
115, 118). We found no correlation between the levels of iNOS and tumour grade 
or stage, although GIII tumours expressed higher levels of mRNA for iNOS. 
Further stratification revealed that the high levels of iNOS mRNA expression 
seen in patients with GIII tumours were found in the patients with CIS (alone 
or concomitant to a papillary GIII tumour). is observation may be related 
to the enhanced growth capacity of this tumour. CIS is a high-grade (GIII) 
tumour presenting as a flat lesion, and has a high risk of progressing into invasive 
cancer (104). is risk is higher than that seen in papillary TaGIII tumours (105) 
implicating that CIS is a seperate entity of bladder cancer. Alternatively, the 
higher levels of iNOS mRNA and protein levels, as well as the higher levels of 
NO produced in patients with CIS, may originate from inflammatory cells in the 
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mucosa of the bladder as a response to an immune mediated host defence reaction. 
is is in line with findings by Klotz et al., describing that iNOS is localized in 
invading macrophages and neutrophiles in bladder cancer patients (205). Further 
investigations with immunohistochemistry to identify the site of NO production 
would be of inportance in understanding the involvement of NO in CIS of the 
bladder. 
 It is plausible that iNOS expression and activity in part is affected by 
polymorphisms and the iNOS promoter (-2.6 Kb) microsatellite (CCTTT)n 
polymorphism has been correlated to the development and aggressiveness of 
bladder cancer, thus further supporting the involvement of NO in bladder 
tumour biology (154, 155). Patients with a long set of repeats of the (CCTTT)n 
polymorphism had a lower risk of developing bladder cancer but a higher risk for 
stage progression and cancer specific death once tumour hade developed (155). It 
has been suggested that patients with a long set of repeats for this polymorphism 
have a more active promoter, thus leading to increased NO production (206, 
207). Ryk et al., suggested that a more active version of iNOS could be beneficial 
before the development of a bladder tumour since higher NO production would 
give rise to a more potent host-defence reaction. On the contrary, in patients who 
develop bladder tumours, higher iNOS activity could promote angiogenesis, cause 
further aggressiveness and through the formation of reactive nitrogen species 
repress macrophage activity. In addition, polymorphisms in the eNOS gene have 
been found to affect bladder cancer development and aggressiveness (Ryk et al., 
manuscript under revision in Nitric Oxide: Biology and Chemistry).
5.3 nitric oxide in bcg treatment for bladder cancer
BCG treatment is considered the most effective intravesical treatment for NMIBC 
and is golden standard for treating CIS (126). Although major efforts have been 
made to elucidate its mode of action the exact mechanism through which BCG 
elicits tumour eradication is not fully understood. As reviewed by Brandau (125), 
compelling evidence has been put forward suggesting that BCG triggers a strong 
non-specific inflammatory immune response with T-cell involvement that, 
together with macrophages, result in cytotoxic effects. Several studies propose 
that NO also actively mediate some of the anti tumour effects seen after BCG 
treatment (112, 118). 
 In this work we have demonstrated elevated levels of NO formation in the 
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urinary bladder after BCG treatment and that these levels corresponded to 
elevated levels of iNOS at both transcriptional and protein levels. ese findings 
are in line with previous reports on elevated levels of endogenously formed NO in 
the bladder after BCG treatment (11, 118) and the presence of iNOS protein and 
increased iNOS activity in the bladder mucosa following BCG instillations (118, 
132). We found that iNOS staining was located to the urothelium, predominantly 
the umbrella cells, and to immune competent cells e.g. macrophages located in 
clusters and individually in the submucosa. It is likely that a majority of the NO 
seen in the urinary bladder after BCG treatment originates from the urothelium 
and the inflammatory cells in the submucosa.
 In vitro studies have demonstrated both tumouricidal and tumor-promoting 
effects of NO on tumour cells (208, 209) but the massive production seen after 
BCG treatment is most likely to have deleterious effects on the tumour cells. 
Jansson et al., and Morcos et al., (112, 118, 129) showed that the induction of 
iNOS activity in bladder cancer cells inhibited cell growth and that NO could 
induce apoptosis in bladder cancer cells. 
 Several of the cytokines found in urine in BCG treated bladder cancer patients 
can induce NOS activity (7) and when added to bladder cancer cell cultures 
these cytokines caused growth arrest and apoptosis, which was not the case when 
adding a NOS inhibitor together with the cytokine mixture, suggesting that NO/
NOS pathways mediated apoptosis (112). is is in line with other studies that 
show growth arrest and apoptosis induced by increased iNOS activity and NO 
production following stimulation with cytokines (210). 
 Macrophages are thought to play an important role in BCG induced cytotoxicity 
and NO has been implicated to participate in this effect since NO is considered one 
of the main factors responsible for the cytotoxic activity that macrophages exert 
on tumour cells (211). Interestingly, BCG was one of the first compounds shown 
to induce iNOS dependent macrophage tumour cytotoxicity (1). e mechanisms 
for NO induced cytotoxicity have been attributed to intracellular iron loss with 
inhibition of mitochondrial respiration (1), inhibition of ribonucleotide reductase 
activity leading to the inhibition of DNA synthesis (133) and DNA strand breaks 
caused by peroxynitrite (164). 
 Even though macrophage derived NO has been established as an important 
anti-neoplastic mediator the excessive NO production may also suppress 
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macrophage activity and have deleterious effects on non-tumour surrounding 
tissue (212). is illustrates the complexity of NO signalling and the fine balance 
between tumouricidal activity, on one hand, and negative effects on the immune 
cells, on the other hand.
 Despite being the best bladder sparing treatment option for patients with high 
risk NMIBC a large proportion of patients (30-35%) do not respond to BCG 
treatment. is effect could possibly be due to an acquired resistance to NO that 
has been reported in both macrophages and tumour cell lines (213). ese studies 
implicate that a prolonged exposure to low doses of NO later offers protection to a 
secondary exposure of higher levels of NO. 
 e high levels of NO seen after BCG treatment in addition to the known 
cytotoxic effects of NO on bladder tumour cells support the notion that NO 
might act as an effector molecule in BCG induced tumour eradication. However, 
the need for molecular markers to identify those at risk for BCG failure is crucial 
since radical surgery in BCG non-responders may have a less favourable prognosis 
than those undergoing immediate cystectomy (128). Polymorphisms may be 
associated to drug metabolism and thus treatment response (138-140) and it is 
plausible that polymorphisms could also be one factor responsible for the fact 
that 30-35 % of the BCG treated patients do not respond to treatment. us, we 
studied the influence of iNOS and eNOS polymorphisms on the outcome after 
BCG treatment. We found that patients homozygous or heterozygous for a long 
set of iNOS (CCTTT)n repeats had a higher risk for cancer specific death as 
compared to those who did not. In addition, the eNOS -786T>C polymorphism 
influenced outcome after BCG treatment, showing a lower risk for cancer specific 
death and disease progression in patients with the TT genotype. e same was 
also noted for the eNOS Glu298Asp polymorphism, where the GG genotype 
responded better to BCG.
 For the iNOS (CCTTT)n promoter polymorphism it has been suggested that a 
long set of repeats give rise to a more active promoter thus leading to increased NO 
production (206, 207). is could theoretically be prometastatic due to promoted 
angiogenesis and a repressed macrophage activity, but could also cause resistance 
to the high levels of NO seen after BCG treatment. On the contrary, the C-allele 
in the eNOS -786T>C promoter polymorphism is associated with a less active 
promoter (214, 215) which is also the case for the T-allele in the eNOS intragenic 
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Glu298Asp polymorphism (216). ese findings reflect the differential response 
frequently encountered when studying NO and its pathways. In this scenario it 
may reflect the concentration and duration of NO produced by eNOS and iNOS, 
and that the NO produced from eNOS might be too low to have the ability to 
cause an acquired resistance against NO and that the effect on BCG treatment 
response seen in these patients are mediated through other mechanisms.

CONCLUDING REMARKS AND
FUTURE PERSPECTIVES
• In patients with classic BPS/IC iNOS immune labelling was localized 
to the urothelium and immune competent cells within the urothelium 
and submucosa. In addition, iNOS mRNA and protein expression was 
elevated in patients with classic BPS/IC as compared to control subjects. 
e endogenously formed NO was significantly higher in BPS/IC 
patients than in controls. 
 ese data further support a possible role for NO in the pathogenesis 
of BPS/IC and that drugs targeting the NO/NOS pathways may in the 
future be useful in the treatment for this disease.
• Endogenous NO production was elevated in patients with CIS of 
the bladder, both in primary CIS but also in CIS with a concomitant 
papillary GIII tumour. Also mRNA expression and protein levels for 
iNOS was significantly higher in biopsies from CIS lesions as compared 
to papillary tumours and healthy controls. is could reflect the enhanced 
growth potential in CIS but could also be caused by an increased host-
defence reaction. Further investigation of the site for NO production in 
CIS lesions need to be done. In addition elevated NO measured at the 
time of cystoscopy could in the absence of a UTI be a marker for CIS. In 
these cases cystoscopy with fluorochromes could be used in order to find 
possible primary or concomitant CIS.
• In BCG treated patients iNOS expression at transcriptional and protein 
levels are elevated in bladder biopsies. iNOS activity is located in the 
urothelium and in the immune competent cells in the submucosa. Also 
luminal NO formation is increased after BCG treatment. is further 
supports the notion that NO might mediate some of the anti tumour 
effects exerted by BCG, both directly but also through macrophage 
induced NO cytotoxicity.

• Polymorphisms in the iNOS and eNOS genes may influence the outcome 
after BCG treatment. In patients not carrying a long set of (CCTTT)n 
repeats there was a significantly lower risk for cancer specific death in 
the BCG treated group while there was no difference found in patients 
with a long set of (CCTTT)n repeats. For the eNOS -786T>C promoter 
polymorphism patients with the TT genotype had a lower risk for cancer 
specific death and disease progression, which was also the case for the GG 
genotype in the eNOS intragenic Glu298Asp polymorphism. is further 
supports a possible involvement for NO in bladder cancer biology and in 
BCG treatment for bladder cancer. In addition, this may have clinical 
implications in the selection of patients to BCG treatment, allowing 
those at risk for BCG failure earlier initiation of other treatments, such as 
cystectomy.
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